| Drug Name: | Moxalactam (64952-97-2) |
|---|---|
| PubChem ID: | 47499 |
| SMILES: | CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O |
| InchiKey: | JWCSIUVGFCSJCK-CAVRMKNVSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 520.48 |
| LogP | : | -1.1277 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 12 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 206.3 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Warfarin (81-81-2) | Hypoprothrombinaemia | Additive | Cephalosporins with an N-methylthiotetrazole side-chain can, like the oral anticoagulants, act as vitamin K antagonists to reduce the production of some blood clotting factors. They can therefore cause bleeding on their own. | Enhanced bleeding with cefoxitin or moxalactam Statistical analysis within a defined population of 1493 patients |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category